Naviscan teams with Neoprobe on cancer imaging
Naviscan has entered into an exclusive licensing agreement with Neoprobe as a partner to develop its patented imaging technology.

Most of the patents in Naviscan's intellectual property portfolio were designed for organ-specific molecular imaging. One such patent, now licensed to the Dublin, Ohio-based Neoprobe, enables a gamma ray detector, or a gamma probe, to translate gamma emission data into a 3D representation of a gamma-emitting source, such as a malignant lesion or tumor, Naviscan said.

Partnering with Neoprobe, according to the San Diego-based Naviscan, allows its technology to be developed in surgical cancer applications.